Back to Search
SARA FELTON, PHARMD
PHARMD
Pharmacist
NPI: 1679241848Individual
Specialties, Licenses & Credentials
PharmacistPrimary
Pharmacist
Code: 183500000X
RP454475(PA)03440283(OH)
Research & Publications (13)
1,25(OH)2 vitamin d inhibits foam cell formation and suppresses macrophage cholesterol uptake in patients with type 2 diabetes mellitus.
PMID 19667238·Circulation·2009
7-preclinical
Massage therapy versus simple touch to improve pain and mood in patients with advanced cancer: a randomized trial.
PMID 18794556·Ann Intern Med·2008
4-observational
Associating the mesoscale fiber organization of the tongue with local strain rate during swallowing.
PMID 18456271·J Biomech·2008
8-other
Community-based preferences for stool cards versus colonoscopy in colorectal cancer screening.
PMID 18157581·J Gen Intern Med·2008
8-other
Developing treatment and control conditions in a clinical trial of massage therapy for advanced cancer.
PMID 19087757·J Soc Integr Oncol·2007
8-other
Mechanical basis for lingual deformation during the propulsive phase of swallowing as determined by phase-contrast magnetic resonance imaging.
PMID 17395759·J Appl Physiol (1985)·2007
4-observational
Analysis of responses to valerian root extract in the feline pulmonary vascular bed.
PMID 14736362·J Altern Complement Med·2003
7-preclinical
A phase I study of pivaloyloxymethyl butyrate, a prodrug of the differentiating agent butyric acid, in patients with advanced solid malignancies.
PMID 12114414·Clin Cancer Res·2002
3-trial
Cause-specific mortality associated with HIV and HTLV-II infections among injecting drug users in the USA.
PMID 11426075·AIDS·2001
8-other
Phase I and pharmacokinetic study of NSC 655649, a rebeccamycin analog with topoisomerase inhibitory properties.
PMID 11387367·J Clin Oncol·2001
3-trial
Phase I and pharmacokinetic study of BMS-184476, a taxane with greater potency and solubility than paclitaxel.
PMID 11331328·J Clin Oncol·2001
3-trial
Phase I and pharmacokinetic study of irofulven, a novel mushroom-derived cytotoxin, administered for five consecutive days every four weeks in patients with advanced solid malignancies.
PMID 11118470·J Clin Oncol·2000
8-other
Phase I and pharmacokinetic study of the differentiating agent vesnarinone in combination with gemcitabine in patients with advanced cancer.
PMID 11099327·J Clin Oncol·2000
3-trial
Data courtesy of the U.S. National Library of Medicine (NLM). Ltrl is not affiliated with or endorsed by NLM.
Contact & Hours
- Address
- 4000 JOHNSON RD
STEUBENVILLE, OH 43952 - Phone
- (740) 264-8232
Quick Facts
- NPI
- 1679241848
- Entity Type
- Individual
- Gender
- Female
- Medicare
- Not confirmed
- Specialties
- 2
- Locations
- 1
- Publications
- 13
Are you this provider?
Claim Your Profile